Patent · US Expired

Modified vaccinia ankara virus variant

US7189536B2 · kind B2 · utility

28Cited by

19References

13Claims

0Family size

Assignee

Bavarian Nordic A/S · DK

Inventors

Paul Chaplin · Munich, DE
Paul Howley · Scone, AU
Christine Meisinger · Gröbenzell, DE

Key dates

Filing date	May 16, 2003
Grant date	Mar 13, 2007
Priority date	—
Expiry date	Aug 14, 2024

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2740/16322
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus and characterized by the loss of its capability to reproductively replicate in human cell lines. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a medicament or vaccine. A method is provided for inducing an immune response in individuals who may be immune-compromised, receiving antiviral therapy, or have a pre-existing immunity to the vaccine virus. In addition, a method is provided for the administration of a therapeutically effective amount of the virus, or its recombinants, in a vaccinia virus prime/vaccinia virus boost innoculation regimen.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.